432 related articles for article (PubMed ID: 23547210)
1. Etanercept improves lipid profile and oxidative stress measures in patients with juvenile idiopathic arthritis.
De Sanctis S; Marcovecchio ML; Gaspari S; Del Torto M; Mohn A; Chiarelli F; Breda L
J Rheumatol; 2013 Jun; 40(6):943-8. PubMed ID: 23547210
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor necrosis factor α targets protein kinase B/c-Akt-induced resistance of effector cells to suppression in juvenile idiopathic arthritis.
Wehrens EJ; Vastert SJ; Mijnheer G; Meerding J; Klein M; Wulffraat NM; Prakken BJ; van Wijk F
Arthritis Rheum; 2013 Dec; 65(12):3279-84. PubMed ID: 23983021
[TBL] [Abstract][Full Text] [Related]
3. Relation of interleukin-6, TNF-alpha and interleukin-1alpha with disease activity and severity in juvenile idiopathic arthritis patients.
Spîrchez M; Samaşca G; Iancu M; Bolba C; Miu N
Clin Lab; 2012; 58(3-4):253-60. PubMed ID: 22582498
[TBL] [Abstract][Full Text] [Related]
4. Lipid profiles alter from pro-atherogenic into less atherogenic and proinflammatory in juvenile idiopathic arthritis patients responding to anti TNF-α treatment.
Yeh KW; Lee CM; Chang CJ; Lin YJ; Huang JL
PLoS One; 2014; 9(6):e90757. PubMed ID: 24603504
[TBL] [Abstract][Full Text] [Related]
5. Improvement in health-related quality of life for children with juvenile idiopathic arthritis after start of treatment with etanercept.
Klotsche J; Minden K; Thon A; Ganser G; Urban A; Horneff G
Arthritis Care Res (Hoboken); 2014 Feb; 66(2):253-62. PubMed ID: 23983081
[TBL] [Abstract][Full Text] [Related]
6. Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis.
Tynjälä P; Lahdenne P; Vähäsalo P; Kautiainen H; Honkanen V
Ann Rheum Dis; 2006 Aug; 65(8):1044-9. PubMed ID: 16449314
[TBL] [Abstract][Full Text] [Related]
7. Cytokine Biomarkers of Disease Activity and Therapeutic Response after Initiating Methotrexate Therapy in Patients with Juvenile Idiopathic Arthritis.
Funk RS; Chan MA; Becker ML
Pharmacotherapy; 2017 Jun; 37(6):700-711. PubMed ID: 28475276
[TBL] [Abstract][Full Text] [Related]
8. Etanercept treatment improves longitudinal growth in prepubertal children with juvenile idiopathic arthritis.
Vojvodich PF; Hansen JB; Andersson U; Sävendahl L; Hagelberg S
J Rheumatol; 2007 Dec; 34(12):2481-5. PubMed ID: 18050366
[TBL] [Abstract][Full Text] [Related]
9. Proinflammatory cytokines in monitoring the course of disease and effectiveness of treatment with etanercept (ETN) of children with oligo- and polyarticular juvenile idiopathic arthritis (JIA).
Kaminiarczyk-Pyzalka D; Adamczak K; Mikos H; Klimecka I; Moczko J; Niedziela M
Clin Lab; 2014; 60(9):1481-90. PubMed ID: 25291944
[TBL] [Abstract][Full Text] [Related]
10. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P
Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
[TBL] [Abstract][Full Text] [Related]
11. TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis.
Gudbrandsdottir S; Larsen R; Sørensen LK; Nielsen S; Hansen MB; Svenson M; Bendtzen K; Müller K
Clin Exp Rheumatol; 2004; 22(1):118-24. PubMed ID: 15005015
[TBL] [Abstract][Full Text] [Related]
12. Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy.
Aikawa NE; França IL; Ribeiro AC; Sallum AM; Bonfa E; Silva CA
Vaccine; 2015 Jan; 33(5):604-9. PubMed ID: 25554240
[TBL] [Abstract][Full Text] [Related]
13. The impact of disease activity and tumour necrosis factor-α inhibitor therapy on cytokine levels in juvenile idiopathic arthritis.
Walters HM; Pan N; Lehman TJ; Adams A; Kalliolias GD; Zhu YS; Santiago F; Nguyen J; Sitaras L; Cunningham-Rundles S; Walsh TJ; Toussi SS
Clin Exp Immunol; 2016 Jun; 184(3):308-17. PubMed ID: 26934060
[TBL] [Abstract][Full Text] [Related]
14. Effects of anti-TNF therapy on glucose metabolism in patients with ankylosing spondylitis, psoriatic arthritis or juvenile idiopathic arthritis.
da Silva BS; Bonfá E; de Moraes JC; Saad CG; Ribeiro AC; Gonçalves CR; de Carvalho JF
Biologicals; 2010 Sep; 38(5):567-9. PubMed ID: 20638299
[TBL] [Abstract][Full Text] [Related]
15. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.
Zivojinovic SM; Pejnovic NN; Sefik-Bukilica MN; Kovacevic LV; Soldatovic II; Damjanov NS
J Rheumatol; 2012 Jan; 39(1):18-21. PubMed ID: 22133625
[TBL] [Abstract][Full Text] [Related]
17. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
[TBL] [Abstract][Full Text] [Related]
18. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
Gerloni V; Pontikaki I; Gattinara M; Fantini F
Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study.
Horneff G; Foeldvari I; Minden K; Trauzeddel R; Kümmerle-Deschner JB; Tenbrock K; Ganser G; Huppertz HI
Arthritis Rheumatol; 2015 May; 67(8):2240-9. PubMed ID: 25891010
[TBL] [Abstract][Full Text] [Related]
20. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis.
Tynjälä P; Lindahl P; Honkanen V; Lahdenne P; Kotaniemi K
Ann Rheum Dis; 2007 Apr; 66(4):548-50. PubMed ID: 17068061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
